secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001619856-23-000050
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Biosciences doses first patient in Phase 1 trial of CB-011 for multiple myeloma
--------------------------------------------------------------------------------

- First patient dosed with CB-011 at dose level 1 (50x10^6 CAR-T cells) in CaMMouflage Phase 1 trial for relapsed/refractory multiple myeloma.
- CB-011 is an allogeneic anti-BCMA CAR-T cell therapy with immune cloaking via B2M removal and B2M-HLA-E transgene insertion.
- Trial is open-label, 3+3 dose escalation (Part A) followed by dose expansion (Part B); excludes prior CAR-T or BCMA therapy within 3 months.
- CB-011 is Caribou's second allogeneic CAR-T program to enter the clinic.
- Company plans to continue enrollment at dose level 1 and provide dose clearance updates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000050/0001619856-23-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000050/crbu-20230329.htm
  HTML page:      https://secwatch.observer/filing/0001619856-23-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer